Rimegepant orally disintegrating tablets in the acute treatment of migraine: a profile of their use
AbstractRimegepant orally disintegrating tablets (ODT) for sublingual or oral use (Nurtec ™ ODT) are a valuable option for the acute treatment of migraine ± aura in adults, especially those with contraindications, treatment failure, or tolerability issues with triptans. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist, and is the first, and currently only , drug in this class available as an ODT formulation in the USA. A single sublingual dose of rimegepant ODT 75 mg provided freedom from pain, freedom from the most bothersome migraine symptoms (e.g., nausea, phonophobia, photophobia), and...
Source: Drugs and Therapy Perspectives - October 30, 2020 Category: Drugs & Pharmacology Source Type: research
Tofacitinib in ulcerative colitis: a profile of its use
AbstractOral tofacitinib (Xeljanz®) is a first-in-class, small molecule janus kinase (JAK) inhibitor that is approved for the treatment of moderate to severe ulcerative colitis in adults who have inadequately responded to, or are intolerant of, conventional therapy or a biological agent in the EU and in adults who have inadequately responded to, or are intolerant of, a tumour necrosis factor antagonist in the USA. In the pivotal phase 3 trials, tofacitinib induction (10 mg twice daily) and maintenance (5 or 10 mg twice daily) treatment significantly improved clinical and endoscopic findings of ulcerative colitis and healt...
Source: Drugs and Therapy Perspectives - October 28, 2020 Category: Drugs & Pharmacology Source Type: research
Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 28, 2020 Category: Drugs & Pharmacology Source Type: research
Upadacitinib in rheumatoid arthritis: a profile of its use
AbstractUpadacitinib (Rinvoq ™), an oral Janus kinase (JAK) 1 inhibitor, is approved as monotherapy or in combination with nonbiological disease-modifying antirheumatic drugs (DMARDs), including methotrexate, in adult patients with moderate to severely active rheumatoid arthritis (RA) who have responded inadequately to, or wh o are intolerant to one or more DMARD. Across phase 3 trials in patients with RA, once-daily upadacitinib treatment was generally well tolerated and associated with rapid and clinically relevant disease remission or low disease activity when administered as monotherapy or in combination conventional...
Source: Drugs and Therapy Perspectives - October 26, 2020 Category: Drugs & Pharmacology Source Type: research
Impact of clinical pharmacists on adherence to stress ulcer prophylaxis protocol in critically ill Egyptian patients: a comparative study
ConclusionClinical pharmacists ’ daily interventions decreased non-adherence to the SUP protocol, and provided a significant decrease in hospital expenditures with no influence on adverse effects. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 19, 2020 Category: Drugs & Pharmacology Source Type: research
Other options usually better than benzodiazepines in alleviating dyspnoea, sleeping problems and anxiety in COPD patients
AbstractChronic obstructive pulmonary disease (COPD) is common, especially in older people, and causes progressive dyspnoea that is often accompanied by anxiety and depression. Benzodiazepines (BZDs) are regularly prescribed to COPD patients but can cause significant respiratory adverse events. There are usually better treatment alternatives, such as pulmonary rehabilitation and treatment with antidepressants. The increasing prescription of BZDs with age is concerning, particularly as COPD becomes more prevalent. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 17, 2020 Category: Drugs & Pharmacology Source Type: research
Lumateperone in schizophrenia: a profile of its use
AbstractOral lumateperone (Caplyta®) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults in the USA. As a mechanistically novel agent that selectively and simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, it offers a new option for the management of this severe and debilitating mental disorder. Across three phase 2 or 3 studies in patients with an acute exacerbation of schizophrenia, double-blind treatment with lumateperone 42 mg/day for 4–6 weeks significantly improved psychotic symptoms and global disease severity compared with placebo. Additionally, open...
Source: Drugs and Therapy Perspectives - October 5, 2020 Category: Drugs & Pharmacology Source Type: research
Severe hypertension in children needs a rapid response and thorough investigation
AbstractSevere hypertension (HTN) in children requires urgent treatment. If end organ renal, neurological or cardiac damage is suspected, intravenous antihypertensives, such as hydrazaline, labetolol or nicardipine, should be administered immediately and admission to an intensive care unit is imperative. Where symptoms are milder, oral medications may suffice. Serious underlying conditions are likely in younger children or those with very high blood pressure and all cases of severe HTN should be carefully investigated. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 5, 2020 Category: Drugs & Pharmacology Source Type: research
Self-medication during Covid-19 pandemic: challenges and opportunities
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 2, 2020 Category: Drugs & Pharmacology Source Type: research
Correction to: Lemborexant in insomnia disorder: a profile of its use
The author has alerted us to the following errors, and the following corrections should be noted. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - September 30, 2020 Category: Drugs & Pharmacology Source Type: research
“Over-the-counter” cannabidiol (CBD) sold in the community pharmacy setting in Colorado
ConclusionThe findings of this study illustrate the extensive variability of cannabidiol products and the importance of communication with people considering their use. Counseling those utilizing these products may help to avoid drug –drug or drug–supplement interactions and adverse events. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - September 28, 2020 Category: Drugs & Pharmacology Source Type: research
Olopatadine/mometasone combination nasal spray in allergic rhinitis: a profile of its use
AbstractOlopatadine/mometasone furoate combination nasal spray (Ryaltris®; referred to hereafter as olopatadine/mometasone), a convenient fixed-dose combination (FDC) of the antihistamine olopatadine and the corticosteroid mometasone furoate, is approved in Australia for the treatment of symptoms associated with allergic rhinitis (AR) and rhinoconjunctivitis in patients 12 years of age and older. Olopatadine/mometasone is an effective treatment for seasonal and perennial AR, providing statistically significant and clinically meaningful relief of nasal symptoms relative to monocomponents and/or placebo in clinical trials...
Source: Drugs and Therapy Perspectives - September 26, 2020 Category: Drugs & Pharmacology Source Type: research
Cosmetic disfigurement from black salve
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - September 25, 2020 Category: Drugs & Pharmacology Source Type: research
Exploring the utility of a spontaneous adverse drug reaction reporting system in identifying drug –drug interactions between antiretrovirals, antitubercular drugs, and cotrimoxazole: a case/non-case analysis
ConclusionIt is feasible to conduct signal detection analyses for DDIs within relatively small SRS databases. However, the observed potential SDR for the respective DDI should be investigated further as the method is only a hypothesis-generation analysis. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - September 21, 2020 Category: Drugs & Pharmacology Source Type: research
Adherence of patients with type 2 diabetes to refills and medications: a comparison between ‘telephone and collect’ and conventional counter services in a health clinic
ConclusionsPharmacy VAS could be an effective option in improving adherence to medications and refills in patients with T2DM. Further research is needed to assess its generalizability to other chronic diseases and to various types of healthcare settings in Malaysia. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - September 13, 2020 Category: Drugs & Pharmacology Source Type: research
